Department of Renal Medicine, Hull & East Yorkshire Hospitals NHS Trust & Hull York Medical School, East Yorkshire, UK.
Eur J Haematol. 2012 Sep;89(3):187-97. doi: 10.1111/j.1600-0609.2012.01819.x. Epub 2012 Jul 21.
Beta-thalassaemia is characterised by progressive anaemia necessitating regular blood transfusions to sustain life. With the advent of effective chelating agents that can reduce the iron burden and extend patients' survival, renal disease, as in other ageing populations, has become more prevalent. In recent years, chronic kidney disease (CKD) has become overwhelming; indeed, approximately 8% or 6 million people of the UK population has evidence of CKD. Several factors, which occur in patients with thalassaemia, account for the relative explosion of renal disease in the general population including increasing age, diabetes, hypertension and the advent of novel measures of renal function facilitating early detection of kidney disease. In addition, some patients with thalassaemia develop renal tubular dysfunction related to the disease itself, the effects of iron overload and the effects of chelator therapy, while other patients have an increased creatinine clearance leading to hyperfiltration. More recently, there is a noticeable increasing prevalence of impaired renal function and proteinuria because of several putative factors including chelators. We review current data on the potential mechanisms leading to renal abnormalities seen in patients with thalassaemia, the potential effects of iron loading within the kidney and the potential renal effects of chelator therapy. This article gives a speculative account of possible mechanisms and theories to consider providing pause for thought and direct future research in this area.
β-地中海贫血的特征是进行性贫血,需要定期输血以维持生命。随着能够降低铁负荷并延长患者生存时间的有效螯合剂的出现,与其他老年人群一样,肾脏疾病变得更加普遍。近年来,慢性肾脏病(CKD)已成为压倒性问题;事实上,英国约有 8%或 600 万人有 CKD 的证据。地中海贫血患者中出现的几种因素导致了普通人群中肾脏疾病的相对爆发,包括年龄增长、糖尿病、高血压以及新型肾功能检测方法的出现,这有助于早期发现肾脏疾病。此外,一些地中海贫血患者会出现与疾病本身、铁过载以及螯合剂治疗有关的肾小管功能障碍,而其他患者则会出现肌酐清除率增加导致的超滤。最近,由于多种潜在因素,包括螯合剂,肾功能受损和蛋白尿的患病率明显增加。我们回顾了目前关于地中海贫血患者中出现肾脏异常的潜在机制、肾脏中铁负荷的潜在影响以及螯合剂治疗的潜在肾脏影响的相关数据。本文对可能的机制和理论进行了推测性讨论,为该领域的进一步研究提供了思考和指导。